Chang Gung University

Chang Gung Memorial Hospital, Linkou

S&t Biomed Co., Ltd.

Yu-Sun Chang

Jau-Song Yu

Lih-Chyang Chen

Tseng-Fu Lu

Chao-Sung Lai

Chia-Chun Chen

Kai-Ping Chang

Pao-Hsien Chu

Yi-Ting Chen

I-Shun Wang

Jinn-Shiun Chen

Chou Chien

Jyh-Ping Chen

Ting-Chun Yu

Wen-Yu Chuang

Yi-Ting Lin

Po-Lung Yang

Ngan-Ming Tsang

Shu-Chen Liu

Kuei-Tien Chen

Err-Cheng Chan

Lai-Chu See

Wei-Fan Chiang

Pei-Chun Fan

Ya-Ting Chang

Jau-song Yu

Yi-Ming Shyr

A method for determining a human subject's risk of developing acute kidney injury (AKI) from acute myocardial infarction (AMI) includes: obtaining a blood sample; determining at least two miRNA expression levels therein, which are selected from miR-23a-3p, miR-24-3p, and miR-145-5p expression levels; calculating probability of developing AKI from AMI based on the at least two miRNA expression levels and a logistic regression model; comparing the probability with a predetermined standard; and determining that the human subject is at the risk of developing AKI when the probability is higher than the predetermined standard. A composition may be administered to the human subject for inhibiting development of AKI, if any.

Method for determining the risk of developing acute kidney injury in a human subject with acute myocardial infarction and inhibiting such development

Disclosed herein is a method of determining whether a subject has or is at risk of developing a cancer. The method comprises, obtaining a sample from the subject; determining the levels of at least two target polypeptides, which are selected from the group consisting of, ANXA2, HSPA5, KNG1 and MMP1; and assessing whether the subject has or is at risk of developing the cancer based on the levels of target polypeptides. The present method provides a potential means to diagnose and predict the occurrence of oral squamous cell carcinoma, and accordingly, the subject in need thereof could receive a suitable therapeutic regimen in time.

Method for cancer diagnosis and prognosis

Embodiments relate to serological markers for detecting the colorectal cancer and applications of the serological markers. A phospholipid scramblase1 (PLSCR1), a stomatin-like protein 2 (STOML2) or a transport protein Sec61&#x3b2; (SEC61&#x3b2;) increases expression in the blood at the earlier stage of the colorectal cancer. Detecting the expression of the PLSCR1, STOML2 or SEC61&#x3b2; protein or an induced autoantibody of each protein in a blood sample is used to diagnose the colorectal cancer. Moreover, the serological marker improves the detection efficiency and the sensitivity in detecting the colorectal cancer and is used to predict the prognosis. The serological markers are applied in preparing a detection device or inhibiting the growth of the colorectal cancer cells.

Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells

A method for evaluation of cancer diagnosis following cancer radiotherapy, comprising: providing a serum sample of a cancer patient prior to the cancer radiotherapy; and measuring a leukemia inhibitory factor concentration in the serum sample. Also provided is a method for potentiation of cancer radiotherapy, comprising: administrating a leukemia inhibitory factor inhibitor or a leukemia inhibitory factor receptor inhibitor to a subject in need of the cancer radiotherapy.

Potentiation of nanopharyngeal cancer radiotherapy by inhibitors of leukemia inhibitory factor

The NHplasma treatment by remote plasma is firstly proposed to replace the covalent bonding process during surface modification procedure that for amine bond generation.

[object Object]

The present invention discloses a TP expression-inhibiting compound and a TP expression-inhibiting siRNA sequence, wherein a siRNA sequence partially or completely complementary to the sequence of TP is used to inhibit TP expression, whereby is effectively reduced the survival rate of cancer cells in an anoxic environment.

TP expression-inhibiting compound and siRNA sequence thereof

The present invention discloses an hnRNP K expression-inhibiting compound and a siRNA sequence thereof, wherein a siRNA sequence partially or completely complementary to the sequence of hnRNP K is used to inhibit hnRNP K expression, whereby is effectively reduced the survival rate of cancer cells in an anoxic environment.

hnRNP K expression-inhibiting compound and siRNA sequence thereof

Growing community of inventors

Tao-Yuan, Taiwan

Yu-Sun Chang